Therapeutic applications of nanobots and nanocarriers in cancer treatment

  • Zaitoon Khan
  • , Nimra Khan
  • , Mithra Geetha
  • , Reyhanath Pilakka Veettil
  • , Deepak Mahadev Kasote
  • , Anwarul Hasan
  • , Kishor Kumar Sadasivuni*
  • *Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Cancer remains a pressing global health concern, burdening individuals, families, and healthcare systems worldwide, mainly because of the limited availability of therapeutic options. These days, nanotechnology is revolutionizing cancer research by offering promising drug delivery systems. Among these, nanobots and nanocarriers are key nanotechnology components, offering groundbreaking strategies in cancer therapy by delivering drugs, enhancing diagnostics, and preventing diseases at molecular levels. Nanobots and nanocarriers, engineered at sizes ranging from 1 to 100 nm, demonstrate biocompatibility with cellular systems, offer precise drug delivery, and reduce side effects compared to conventional therapies such as chemotherapy and surgery. Research efforts now focus on transitioning nanobots and nanocarriers from laboratories to clinics, aiming for precision medicine, targeted drug delivery, enhanced therapy efficacy, and minimal side effects. This review aims to highlight the potential of nanobots and nanocarriers in cancer treatment and provide insights into their role in paving the way for clinical applications and improving outcomes in cancer therapy.

Original languageEnglish
Pages (from-to)1305-1324
Number of pages20
JournalAnalytical Sciences
Volume41
Issue number8
DOIs
StatePublished - Aug 2025
Externally publishedYes

Bibliographical note

Publisher Copyright:
© The Author(s) 2025.

Keywords

  • Cancer treatment
  • Drug delivery
  • Nano-formulation
  • Nanobots
  • Nanocarriers

ASJC Scopus subject areas

  • Analytical Chemistry

Fingerprint

Dive into the research topics of 'Therapeutic applications of nanobots and nanocarriers in cancer treatment'. Together they form a unique fingerprint.

Cite this